Cardiovascular and Cerebrovascular Outcomes Risk Reduction Associated With Semaglutide vs Tirzepatide: A Target Trial Emulation.

Azzam AY, Essibayi MA, Rai P, Salim HA, Alhasan MS, Anindo M, Hashem A, Dmytriw AA, Altschul DJ, Yedavalli VS, Feltrin F, Singh S, Milburn J, Lakhani DA

Open source

DOI: 10.1016/j.jacadv.2026.102917
Published: 2026 Jul
Container: JACC. Advances
Publisher: Not recorded
Open access: yes

Credibility signals

limited evidence Score 45/100 under policy 1.0.0. This is a metadata assessment, not a judgment of the paper's conclusions.

Show all credibility signals

cautionDOI registered: No matching Crossref record was present in this response. Source: Crossref; license: CC0 metadata
cautionDOI resolves: No matching Crossref record was present in this response. Source: Crossref; license: CC0 metadata
not scoredDirectory of Open Access Journals: No matching DOAJ record was present in this response. No allow-list match; this is not evidence of low credibility. Source: DOAJ; license: CC0
not scoredMEDLINE indexed: Not checked or no result supplied; no credibility inference made. Source: No authority result supplied; license: Unknown
not scoredOpenAlex core source: Not checked or no result supplied; no credibility inference made. Source: No authority result supplied; license: Unknown
not scoredKnown publisher allow-list: Not checked or no result supplied; no credibility inference made. Source: No authority result supplied; license: Unknown
not scoredROR affiliation: Not checked or no result supplied; no credibility inference made. Source: No authority result supplied; license: Unknown
not scoredRetraction Watch retraction: No retraction notice matched this DOI in the deployed snapshot. No matching event found; coverage may be incomplete. Source: Retraction Watch; license: CC BY 4.0
not scoredRetraction Watch expression of concern: No expression of concern notice matched this DOI in the deployed snapshot. No matching event found; coverage may be incomplete. Source: Retraction Watch; license: CC BY 4.0
not scoredRetraction Watch correction: No correction notice matched this DOI in the deployed snapshot. No matching event found; coverage may be incomplete. Source: Retraction Watch; license: CC BY 4.0
not scoredRetraction Watch reinstatement: No reinstatement notice matched this DOI in the deployed snapshot. No matching event found; coverage may be incomplete. Source: Retraction Watch; license: CC BY 4.0
supportingOpen access status: Normalized open-access status: open. Source: Normalized work metadata; license: Caller-provided; provenance license not supplied to scorer
not scoredPublication license: Not checked or no result supplied; no credibility inference made. Source: No authority result supplied; license: Unknown
not scoredPublication version: A publication version was supplied but is not scored. Source: Normalized work metadata; license: Caller-provided; provenance license not supplied to scorer
cautionMetadata completeness: 5 of 6 scored descriptive metadata groups are present; missing fields increase uncertainty. Source: Normalized work metadata; license: Caller-provided; provenance license not supplied to scorer

Cite this work

BibTeX

@article{allodium:10.1016/j.jacadv.2026.102917,
  title = {Cardiovascular and Cerebrovascular Outcomes Risk Reduction Associated With Semaglutide vs Tirzepatide: A Target Trial Emulation.},
  author = {Azzam AY and Essibayi MA and Rai P and Salim HA and Alhasan MS and Anindo M and Hashem A and Dmytriw AA and Altschul DJ and Yedavalli VS and Feltrin F and Singh S and Milburn J and Lakhani DA},
  year = {2026},
  journal = {JACC. Advances},
  doi = {10.1016/j.jacadv.2026.102917},
  url = {https://doi.org/10.1016/j.jacadv.2026.102917}
}

RIS

TY  - JOUR
TI  - Cardiovascular and Cerebrovascular Outcomes Risk Reduction Associated With Semaglutide vs Tirzepatide: A Target Trial Emulation.
AU  - Azzam AY
AU  - Essibayi MA
AU  - Rai P
AU  - Salim HA
AU  - Alhasan MS
AU  - Anindo M
AU  - Hashem A
AU  - Dmytriw AA
AU  - Altschul DJ
AU  - Yedavalli VS
AU  - Feltrin F
AU  - Singh S
AU  - Milburn J
AU  - Lakhani DA
PY  - 2026
JO  - JACC. Advances
DO  - 10.1016/j.jacadv.2026.102917
UR  - https://doi.org/10.1016/j.jacadv.2026.102917
ER  -

APA

AY, A., MA, E., P, R., HA, S., MS, A., M, A., A, H., AA, D., DJ, A., VS, Y., F, F., S, S., J, M., & DA, L. (2026). Cardiovascular and Cerebrovascular Outcomes Risk Reduction Associated With Semaglutide vs Tirzepatide: A Target Trial Emulation.. JACC. Advances. https://doi.org/10.1016/j.jacadv.2026.102917

Source records

pubmed · retrieved 2026-09-26T00:36:37.355Z